Respiratory Syncytial Virus in Neonates and Infants: New Frontiers for Its Prevention

Résumé fourni par la source

.Respiratory syncytial virus (RSV) is a primary cause of lower respiratory tract infections in infants, with severe cases potentially leading to long-term respiratory issues like asthma. Globally, RSV affects 33.1 million children annually, resulting in 3.2 million hospitalizations. Despite its signifi-cant burden, treatment remains supportive, emphasizing the importance of prevention. This re-view explores current RSV prevention strategies, focusing on advancements in maternal immun-ization and monoclonal antibodies. Maternal vaccination during pregnancy has emerged as a promising approach, with the FDA-approved RSVpreF vaccine demonstrating 81.8% efficacy in reducing severe RSV infections during the first 90 days of life. Additionally, new monoclonal an-tibodies such as Nirsevimab represent key innovations. Nirsevimab offers single-dose protection, showing significant reductions in RSV hospitalizations across various studies and gaining ap-proval for universal use in regions like USA and Europe. Successful immunization programs, as seen in several countries, highlight the potential of broad implementation. While these develop-ments mark progress, further research is essential to optimize protocols, assess long-term out-comes, and expand access, aiming to alleviate RSV’s global health impact on infants and young children.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.